91 related articles for article (PubMed ID: 23773757)
21. Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes.
Bloethner S; Hemminki K; Thirumaran RK; Chen B; Mueller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
Melanoma Res; 2006 Aug; 16(4):297-307. PubMed ID: 16845325
[TBL] [Abstract][Full Text] [Related]
22. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
23. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
[TBL] [Abstract][Full Text] [Related]
24. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
Zebisch A; Staber PB; Delavar A; Bodner C; Hiden K; Fischereder K; Janakiraman M; Linkesch W; Auner HW; Emberger W; Windpassinger C; Schimek MG; Hoefler G; Troppmair J; Sill H
Cancer Res; 2006 Apr; 66(7):3401-8. PubMed ID: 16585161
[TBL] [Abstract][Full Text] [Related]
25. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
Bloethner S; Chen B; Hemminki K; Müller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
Carcinogenesis; 2005 Jul; 26(7):1224-32. PubMed ID: 15760917
[TBL] [Abstract][Full Text] [Related]
26. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas.
Jacob K; Quang-Khuong DA; Jones DT; Witt H; Lambert S; Albrecht S; Witt O; Vezina C; Shirinian M; Faury D; Garami M; Hauser P; Klekner A; Bognar L; Farmer JP; Montes JL; Atkinson J; Hawkins C; Korshunov A; Collins VP; Pfister SM; Tabori U; Jabado N
Clin Cancer Res; 2011 Jul; 17(14):4650-60. PubMed ID: 21610151
[TBL] [Abstract][Full Text] [Related]
27. Frequency of TERT promoter mutations in human cancers.
Vinagre J; Almeida A; Pópulo H; Batista R; Lyra J; Pinto V; Coelho R; Celestino R; Prazeres H; Lima L; Melo M; da Rocha AG; Preto A; Castro P; Castro L; Pardal F; Lopes JM; Santos LL; Reis RM; Cameselle-Teijeiro J; Sobrinho-Simões M; Lima J; Máximo V; Soares P
Nat Commun; 2013; 4():2185. PubMed ID: 23887589
[TBL] [Abstract][Full Text] [Related]
28. Genetics of melanoma tumorigenesis.
Singh M; Lin J; Hocker TL; Tsao H
Br J Dermatol; 2008 Jan; 158(1):15-21. PubMed ID: 18047516
[TBL] [Abstract][Full Text] [Related]
29. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
30. Status of RASSF1A in uveal melanocytes and melanoma cells.
Calipel A; Abonnet V; Nicole O; Mascarelli F; Coupland SE; Damato B; Mouriaux F
Mol Cancer Res; 2011 Sep; 9(9):1187-98. PubMed ID: 21788308
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic B-Raf(V600E) abrogates the AKT/B-Raf/Mps1 interaction in melanoma cells.
Zhang L; Shi R; He C; Cheng C; Song B; Cui H; Zhang Y; Zhao Z; Bi Y; Yang X; Miao X; Guo J; Chen X; Wang J; Li Y; Cheng X; Liu J; Cui Y
Cancer Lett; 2013 Aug; 337(1):125-32. PubMed ID: 23726842
[TBL] [Abstract][Full Text] [Related]
32. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein.
Brummer T; Martin P; Herzog S; Misawa Y; Daly RJ; Reth M
Oncogene; 2006 Oct; 25(47):6262-76. PubMed ID: 16702958
[TBL] [Abstract][Full Text] [Related]
33. Lucky draw in the gene raffle.
Pollock PM; Meltzer PS
Nature; 2002 Jun; 417(6892):906-7. PubMed ID: 12087387
[No Abstract] [Full Text] [Related]
34. BRAF V600E mutation in two distinct meningeal melanocytomas associated with a nevus of Ota.
Muñoz-Hidalgo L; Lopez-Gines C; Navarro L; Callaghan RC; San Miguel T; Gil-Benso R; Quilis V; Botella L; Gonzalez-Darder J; Cerda-Nicolas M
J Clin Oncol; 2014 Jul; 32(20):e72-5. PubMed ID: 24493731
[No Abstract] [Full Text] [Related]
35. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
36. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
[TBL] [Abstract][Full Text] [Related]
37. junB promoter regulation: Ras mediated transactivation by c-Ets-1 and c-Ets-2.
Coffer P; de Jonge M; Mettouchi A; Binetruy B; Ghysdael J; Kruijer W
Oncogene; 1994 Mar; 9(3):911-21. PubMed ID: 8108135
[TBL] [Abstract][Full Text] [Related]
38. [CRAF, a key player in lung adenocarcinomas induced by K-Ras oncogene].
Francoz S; Dubus P
Med Sci (Paris); 2011 Oct; 27(10):820-2. PubMed ID: 22027418
[No Abstract] [Full Text] [Related]
39. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
[TBL] [Abstract][Full Text] [Related]
40. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.
Zuidervaart W; van Nieuwpoort F; Stark M; Dijkman R; Packer L; Borgstein AM; Pavey S; van der Velden P; Out C; Jager MJ; Hayward NK; Gruis NA
Br J Cancer; 2005 Jun; 92(11):2032-8. PubMed ID: 15928660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
